Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $57
Piper Sandler analyst Yasmeen Rahimi maintains $Immunovant(IMVT.US)$ with a buy rating, and maintains the target price at $57.According to TipRanks data, the analyst has a success rate of 36.6% and
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $44 to $60
On Sep 10, major Wall Street analysts update their ratings for $Immunovant(IMVT.US)$, with price targets ranging from $44 to $60.Goldman Sachs analyst Corinne Johnson upgrades to a buy rating, and
Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.
Buy Rating Affirmed for Immunovant Amid Promising IMVT-1402 Clinical Trial Results for Graves' Disease
Immunovant Stock Falls 8% Amid Graves' Disease Program Update
Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained